Seres Therapeutics (MCRB) Receivables - Net (2016 - 2026)

Seres Therapeutics' (MCRB) quarterly Receivables - Net came in at $274000.0 in Q2 2026, up 17.6% quarter-over-quarter from $233000.0 in Q1 2026.

Analysis

Seres Therapeutics (MCRB) Receivables - Net (2016 - 2026) Analysis & Trends

Seres Therapeutics has disclosed Receivables - Net across 8 years of filings, most recently posting $274000.0 for Q2 2026.

In Q2 2026, Receivables - Net changed N/A year-over-year to $274000.0; the TTM figure through Jun 2026 stood at $274000.0 (changed N/A YoY), while the FY2025 annual figure was $14.9 million, up 300.03% from the prior year.
Receivables - Net came in at $274000.0 for Q2 2026 at Seres Therapeutics, up from $233000.0 in the prior quarter.
In the past five years, Receivables - Net ranged from a high of $7.4 million in Q1 2025 to a low of $157000.0 in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn
10	Seres Therapeutics	49.89 Mn	49.89 Mn	-

Historic Data

Download Data